BETHESDA, Md. - An FDA advisory committee on Friday recommended approval of Genzyme Corp.'s Thyrogen (thyrotropin alfa) for a broad range of indications associated with the evaluation of patients being tested for thyroid cancer metastases.

GENZ and thyroid cancer experts who testified on its behalf persuaded the Endocrinologic and Metabolic Drugs Advisory Committee to reject suggestions from FDA officials that the indication be limited to patients who are unable to undergo a radioiodine whole body scan following withdrawal of hormone therapy.